Increased plasma and tumor somatostatin-like immunoreactivity in medullary thyroid carcinoma and small cell lung cancer

B. A. Roos, A. W. Lindall, J. Ells, R. Elde, P. W. Lambert, R. S. Birnbaum

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

To investigate the possible elaboration of somatostatin-like immunoreactivity (SLI) by medullary thyroid carcinoma (MTC) and/or by small cell lung cancer, we have radioimmunoassayed extracts of plasma and tumor tissue from persons with these forms of cancer. These results have been compared with blood and tissue SLI measurements in patients with epidermoid lung cancer and people without detectable neoplastic disease. The upper limit of plasma SLI in 15 control subjects was 37 pg/ml. None of the 19 patients with epidermoid lung cancer had significantly elevated plasma SLI. By contrast, significantly elevated (136-6150 pg/ml) plasma SLI was noted in 3 of 7 cases of MTC and in 4 of 26 cases of small cell lung cancer. When SLI concentrations determined by direct RIA of plasma extracts were compared to SLI values determined by RIA of SLI isolated by immunoadsorbent chromatography, a highly significant direct correlation was noted. At least three SLI species (13,000, 4,000, and 1,600 daltons) were resolved by gel filtration of plasma extracts. SLI was detectable in thyroid tissue (18-77 pg/mg protein); SLI was undetectable (<12 pg/mg) in normal lungs, epidermoid lung cancers, kidneys, and livers. Tissue SLI was detectable in three of five medullary carcinomas (60-9,200 pg/mg) and five of nine small cell lung cancers (14-441 pg/mg). These results suggest that somatostatin is elaborated by certain nonpancreatic cancers. The plasma and tissue SLI heterogeneity detected in thyroid and lung cancers probably reflects the presence of somatostatin, its biosynthetic intermediate(s), and /or their metabolites. While plasma SLI measurement in MTC seems to be of little immediate clinical importance, the presence of SLI may benefit an understanding of MTC and its origin. Despite the relatively low incidence (15%) of SLI elevation in patients with small cell lung cancer, this finding could have clinical importance for gauging the progression of this common neoplastic disease.

Original languageEnglish
Pages (from-to)187-194
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume52
Issue number2
StatePublished - Apr 27 1981

Fingerprint

Small Cell Lung Carcinoma
Tumors
Cells
Plasmas
Neoplasms
Tissue
Lung Neoplasms
somatostatin-like peptides
Medullary Thyroid cancer
Somatostatin
Immunosorbents
Medullary Carcinoma
Gaging
Kidney Neoplasms
Liver Neoplasms
Metabolites
Chromatography
Thyroid Neoplasms
Liver
Gel Chromatography

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Increased plasma and tumor somatostatin-like immunoreactivity in medullary thyroid carcinoma and small cell lung cancer. / Roos, B. A.; Lindall, A. W.; Ells, J.; Elde, R.; Lambert, P. W.; Birnbaum, R. S.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 52, No. 2, 27.04.1981, p. 187-194.

Research output: Contribution to journalArticle

Roos, B. A. ; Lindall, A. W. ; Ells, J. ; Elde, R. ; Lambert, P. W. ; Birnbaum, R. S. / Increased plasma and tumor somatostatin-like immunoreactivity in medullary thyroid carcinoma and small cell lung cancer. In: Journal of Clinical Endocrinology and Metabolism. 1981 ; Vol. 52, No. 2. pp. 187-194.
@article{b00ed457486f4eaf82a9964472b91af1,
title = "Increased plasma and tumor somatostatin-like immunoreactivity in medullary thyroid carcinoma and small cell lung cancer",
abstract = "To investigate the possible elaboration of somatostatin-like immunoreactivity (SLI) by medullary thyroid carcinoma (MTC) and/or by small cell lung cancer, we have radioimmunoassayed extracts of plasma and tumor tissue from persons with these forms of cancer. These results have been compared with blood and tissue SLI measurements in patients with epidermoid lung cancer and people without detectable neoplastic disease. The upper limit of plasma SLI in 15 control subjects was 37 pg/ml. None of the 19 patients with epidermoid lung cancer had significantly elevated plasma SLI. By contrast, significantly elevated (136-6150 pg/ml) plasma SLI was noted in 3 of 7 cases of MTC and in 4 of 26 cases of small cell lung cancer. When SLI concentrations determined by direct RIA of plasma extracts were compared to SLI values determined by RIA of SLI isolated by immunoadsorbent chromatography, a highly significant direct correlation was noted. At least three SLI species (13,000, 4,000, and 1,600 daltons) were resolved by gel filtration of plasma extracts. SLI was detectable in thyroid tissue (18-77 pg/mg protein); SLI was undetectable (<12 pg/mg) in normal lungs, epidermoid lung cancers, kidneys, and livers. Tissue SLI was detectable in three of five medullary carcinomas (60-9,200 pg/mg) and five of nine small cell lung cancers (14-441 pg/mg). These results suggest that somatostatin is elaborated by certain nonpancreatic cancers. The plasma and tissue SLI heterogeneity detected in thyroid and lung cancers probably reflects the presence of somatostatin, its biosynthetic intermediate(s), and /or their metabolites. While plasma SLI measurement in MTC seems to be of little immediate clinical importance, the presence of SLI may benefit an understanding of MTC and its origin. Despite the relatively low incidence (15{\%}) of SLI elevation in patients with small cell lung cancer, this finding could have clinical importance for gauging the progression of this common neoplastic disease.",
author = "Roos, {B. A.} and Lindall, {A. W.} and J. Ells and R. Elde and Lambert, {P. W.} and Birnbaum, {R. S.}",
year = "1981",
month = "4",
day = "27",
language = "English",
volume = "52",
pages = "187--194",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Increased plasma and tumor somatostatin-like immunoreactivity in medullary thyroid carcinoma and small cell lung cancer

AU - Roos, B. A.

AU - Lindall, A. W.

AU - Ells, J.

AU - Elde, R.

AU - Lambert, P. W.

AU - Birnbaum, R. S.

PY - 1981/4/27

Y1 - 1981/4/27

N2 - To investigate the possible elaboration of somatostatin-like immunoreactivity (SLI) by medullary thyroid carcinoma (MTC) and/or by small cell lung cancer, we have radioimmunoassayed extracts of plasma and tumor tissue from persons with these forms of cancer. These results have been compared with blood and tissue SLI measurements in patients with epidermoid lung cancer and people without detectable neoplastic disease. The upper limit of plasma SLI in 15 control subjects was 37 pg/ml. None of the 19 patients with epidermoid lung cancer had significantly elevated plasma SLI. By contrast, significantly elevated (136-6150 pg/ml) plasma SLI was noted in 3 of 7 cases of MTC and in 4 of 26 cases of small cell lung cancer. When SLI concentrations determined by direct RIA of plasma extracts were compared to SLI values determined by RIA of SLI isolated by immunoadsorbent chromatography, a highly significant direct correlation was noted. At least three SLI species (13,000, 4,000, and 1,600 daltons) were resolved by gel filtration of plasma extracts. SLI was detectable in thyroid tissue (18-77 pg/mg protein); SLI was undetectable (<12 pg/mg) in normal lungs, epidermoid lung cancers, kidneys, and livers. Tissue SLI was detectable in three of five medullary carcinomas (60-9,200 pg/mg) and five of nine small cell lung cancers (14-441 pg/mg). These results suggest that somatostatin is elaborated by certain nonpancreatic cancers. The plasma and tissue SLI heterogeneity detected in thyroid and lung cancers probably reflects the presence of somatostatin, its biosynthetic intermediate(s), and /or their metabolites. While plasma SLI measurement in MTC seems to be of little immediate clinical importance, the presence of SLI may benefit an understanding of MTC and its origin. Despite the relatively low incidence (15%) of SLI elevation in patients with small cell lung cancer, this finding could have clinical importance for gauging the progression of this common neoplastic disease.

AB - To investigate the possible elaboration of somatostatin-like immunoreactivity (SLI) by medullary thyroid carcinoma (MTC) and/or by small cell lung cancer, we have radioimmunoassayed extracts of plasma and tumor tissue from persons with these forms of cancer. These results have been compared with blood and tissue SLI measurements in patients with epidermoid lung cancer and people without detectable neoplastic disease. The upper limit of plasma SLI in 15 control subjects was 37 pg/ml. None of the 19 patients with epidermoid lung cancer had significantly elevated plasma SLI. By contrast, significantly elevated (136-6150 pg/ml) plasma SLI was noted in 3 of 7 cases of MTC and in 4 of 26 cases of small cell lung cancer. When SLI concentrations determined by direct RIA of plasma extracts were compared to SLI values determined by RIA of SLI isolated by immunoadsorbent chromatography, a highly significant direct correlation was noted. At least three SLI species (13,000, 4,000, and 1,600 daltons) were resolved by gel filtration of plasma extracts. SLI was detectable in thyroid tissue (18-77 pg/mg protein); SLI was undetectable (<12 pg/mg) in normal lungs, epidermoid lung cancers, kidneys, and livers. Tissue SLI was detectable in three of five medullary carcinomas (60-9,200 pg/mg) and five of nine small cell lung cancers (14-441 pg/mg). These results suggest that somatostatin is elaborated by certain nonpancreatic cancers. The plasma and tissue SLI heterogeneity detected in thyroid and lung cancers probably reflects the presence of somatostatin, its biosynthetic intermediate(s), and /or their metabolites. While plasma SLI measurement in MTC seems to be of little immediate clinical importance, the presence of SLI may benefit an understanding of MTC and its origin. Despite the relatively low incidence (15%) of SLI elevation in patients with small cell lung cancer, this finding could have clinical importance for gauging the progression of this common neoplastic disease.

UR - http://www.scopus.com/inward/record.url?scp=0019367007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019367007&partnerID=8YFLogxK

M3 - Article

C2 - 6109732

AN - SCOPUS:0019367007

VL - 52

SP - 187

EP - 194

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -